Design and baseline characteristics of the CARdiovascular Outcome Trial of LINAgliptin Versus Glimepiride in Type 2 Diabetes (CAROLINA®) (Q35330816)

7 August 2017

Design and baseline characteristics of the CARdiovascular Outcome Trial of LINAgliptin Versus Glimepiride in Type 2 Diabetes (CAROLINA®) (English)

1 reference

7 August 2017

1 reference

1 reference

John M Lachin

6

0 references

Steven E. Kahn

object named as

Steven E Kahn

3

0 references

Julio Rosenstock

2

object named as

Julio Rosenstock

1 reference

7 August 2017

4

Bernard Zinman

1 reference

7 August 2017

7

Mark A Espeland

1 reference

7 August 2017

12

Odd Erik Johansen

1 reference

7 August 2017

1

Nikolaus Marx

1 reference

7 August 2017

John J Kastelein

5

1 reference

7 August 2017

Erich Bluhmki

8

1 reference

7 August 2017

Michaela Mattheus

9

1 reference

7 August 2017

Bart Ryckaert

10

1 reference

7 August 2017

Sanjay Patel

11

1 reference

7 August 2017

Hans-Juergen Woerle

13

1 reference

7 August 2017

language of work or name

English

0 references

publication date

15 March 2015

1 reference

Diabetes and Vascular Disease Research

7 August 2017

1 reference

7 August 2017

12

1 reference

7 August 2017

164-174

1 reference

7 August 2017

3

1 reference

The effects of dipeptidyl peptidase-4 inhibition on microvascular diabetes complications.

7 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4390606

Heart failure, saxagliptin, and diabetes mellitus: observations from the SAVOR-TIMI 53 randomized trial

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4390606

The potential for renoprotection with incretin-based drugs

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4390606

Head-to-head comparison of dipeptidyl peptidase-IV inhibitors and sulfonylureas - a meta-analysis from randomized clinical trials

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4390606

Alogliptin after acute coronary syndrome in patients with type 2 diabetes

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4390606

Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4390606

Rationale and design of the glycemia reduction approaches in diabetes: a comparative effectiveness study (GRADE).

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4390606

Sulphonylurea monotherapy for patients with type 2 diabetes mellitus

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4390606

DPP-4 inhibition and neuroprotection: do mechanisms matter?

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4390606

Cardiovascular outcome trials in type 2 diabetes and the sulphonylurea controversy: rationale for the active-comparator CAROLINA trial

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4390606

Decreased carotid atherosclerotic process by control of daily acute glucose fluctuations in diabetic patients treated by DPP-IV inhibitors.

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4390606

Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4390606

The potential effects of anti-diabetic medications on myocardial ischemia-reperfusion injury

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4390606

Dipeptidyl peptidase-4 inhibitors and preservation of pancreatic islet-cell function: a critical appraisal of the evidence

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4390606

Cardiovascular effects of DPP-4 inhibition: beyond GLP-1.

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4390606

Comparative effectiveness and safety of medications for type 2 diabetes: an update including new drugs and 2-drug combinations

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4390606

Linagliptin, a xanthine-based dipeptidyl peptidase-4 inhibitor with an unusual profile for the treatment of type 2 diabetes

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4390606

Severe hypoglycaemia and cardiovascular disease: systematic review and meta-analysis with bias analysis

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4390606

The metabolism and disposition of the oral dipeptidyl peptidase-4 inhibitor, linagliptin, in humans

26 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4390606

A note on stratifying versus complete random assignment in clinical trials.

26 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4390606

A study of the effects of hypoglycemic agents on vascular complications in patients with adult-onset diabetes. II. Mortality results

26 September 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/25780262

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

2-year efficacy and safety of linagliptin compared with glimepiride in patients with type 2 diabetes inadequately controlled on metformin: a randomised, double-blind, non-inferiority trial

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/25780262

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

C-peptide levels in latent autoimmune diabetes in adults treated with linagliptin versus glimepiride: exploratory results from a 2-year double-blind, randomized, controlled study

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/25780262

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1177/1479164115570301

1 reference

7 August 2017

1 reference

7 August 2017

1 reference